Mayo 2012 Staging Criteria for AL Amyloidosis[1,2]

Biomarker	Threshold	Stages
Troponin	cTnT ≥0.025 ng/mL **OR** hs-cTnT ≥40 ng/L	Stage I No risk factors
BNP	NT-proBNP ≥1800 pg/mL **OR** BNP ≥400 pg/mL	Stage II 1 risk factor
dFLC*	dFLC ≥18 mg/dL	Stage III 2 risk factors
Biomarkers above threshold indicate increased risk of poorer survival outcomes[1,2]		**Stage IV** 3 risk factors

***Including dFLC may improve risk stratification of patients with AL amyloidosis.[1]**

AL, light chain; BNP, B-type natriuretic peptide; cTnT, cardiac troponin T; dFLC, difference in involved and uninvolved serum free light chains; hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal pro-brain natriuretic peptide.

1. Kumar S, et al. *J Clin Oncol.* 2012;30:989-95; **2.** Muchtar E, et al. *Blood.* 2019;133:763-6; **3.** AFFIRM-AL Amyloidosis Study; NCT04973137. Accessed March 2024. https://www.clinicaltrials.gov/study/NCT04973137.

PRTA-MRC00182

AFFIRM-AL STUDY

Inclusion Criteria[3]

Aged ≥18 years

Newly diagnosed AL amyloidosis

Meets criteria for Stage IV with:

NT-proBNP ≤8500 pg/mL

More information about AFFIRM-AL:

prothena®

EU Modified 2004 Mayo Staging[1-3]

Biomarker	Threshold	Stages
Troponin	cTnT ≥0.035 ng/mL **OR** hs-cTnT ≥50 ng/L **OR** cTnI ≥0.1 ng/mL	**Stage I** No risk factors
BNP	NT-proBNP ≥332 pg/mL **OR** BNP ≥81 pg/mL	**Stage II** 1 risk factor
		Stage IIIa 2 risk factors and NT-proBNP <8500 pg/mL or BNP <700 pg/mL
		Stage IIIb 2 risk factors and NT-proBNP ≥8500 pg/mL or BNP ≥700 pg/mL

Biomarkers above threshold indicate increased risk of poorer survival outcomes[1-3]

***Equivalent to BNP ≥400 pg/mL and ≤700 pg/mL.[1]**

†If you think a patient may be eligible for AFFIRM-AL based on troponin and NT-proBNP (or BNP), test for dFLC to determine eligibility for AFFIRM-AL or refer to an AFFIRM-AL trial site for dFLC testing.

AL, light chain; BNP, B-type natriuretic peptide; cTnI, cardiac troponin I; cTnT, cardiac troponin T; dFLC, difference in involved and uninvolved serum free light chains; EU, European Union; hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal pro-brain natriuretic peptide.

1. Muchtar E, et al. *Blood.* 2019;133:763-6; **2.** Palladini G, et al. *Blood.* 2015;126:612-5; **3.** Palladini G, et al. *Blood.* 2020;136:2620-7; **4.** AFFIRM-AL Amyloidosis Study; NCT04973137. Accessed March 2024. https://www.clinicaltrals.gov/study/NCT04973137.

PRTA-MRC00182

AFFIRM-AL STUDY

Biomarker Inclusion Criteria[4]

cTnT ≥0.025 ng/mL **OR** hs-cTnT ≥40 ng/mL

NT-proBNP ≥1800 pg/mL and ≤8500 pg/mL*

dFLC† ≥18 mg/dL

More information about AFFIRM-AL:

prothena®